VivoSeq
Respiratory

Rhinitis, Allergic

3

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Rhinitis, Allergic is an early-stage landscape with 3 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT06436534·50 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of PollenVax, Emulsion for Subcutaneous Injection, in Patients With Allergic Rhinitis Induced by Mugwort (Artemisia Vulgaris) Pollen
Recruiting·KKazakh National Agrarian University·Phase 2·NCT07563439·138 enrolled
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of PollenVax, a Subcutaneous Emulsion, in Patients With Mugwort Pollen-Induced Allergic Rhinitis
Completed·KKazakh National Agrarian University·Phase 1·NCT07317960·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)